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NOVEL METHOD OF ADMINISTERING 
B-BLOCKERS AND NOVEL DOSAGE FORMS 
CONTAINING SAME 
BACKGROUND OF THE INVENTION 
1. Field of the Invention 
The present invention relates to a novel method of 
administering selected known adrenergic B-receptor 
blocking agents, and to novel dosage forms containing 
such agents adapted for nasal administration. 
2. Background Art 
A number of B-adrenergic blocking agents are 
10 
known. Such agents are widely used therapeutically, ' 
chie?y in the management of hypertension and in the 
treatment of angina pectoris, arrhythmias and other 
cardiac conditions, and also possibly in the treatment of 
migraine. Unfortunately, however, these known B 
blockers are inef?ciently and variably absorbed from 
oral dosage forms, probably because of extensive‘ me 
tabolism of the drug in the gastrointestinal tract and/or 
extensive effects of the ?rst pass through the liver. 
The present inventor and his co-workers have previ 
ously reported that one widely used B-blocker, pro 
pranolol, can be effectively administered in nasal dos 
age form. Nasal administration of propanolol has been 
found to provide enhanced bioavailability and mini 
mized variations in blood levels as compared to oral 
administration. See copending Hussain et a1.‘ Applica 
tion Ser. No. 063,176, ?led Aug. 3, 1979; Hussain et al. 
J. Pharm. Sci., Vol. 68, No. 8, September, 1979, page 
1196; Hussain et al, J. Pharm. Sci, Vol. 69, No. 10, 
October, 1980, page 1240; Hussain et al, J. Pharm. Sci, 
Vol. 69, No. 12, December, 1980, pages 1411-1413. 
SUMMARY OF THE INVENTION 
Surprisingly, the present inventor has now found that 
yet other adrenergic B-receptor blocking agents can be 
effectively administered nasally. More speci?cally, the 
present inventor has found that selected B-blockers, 
which differ substantially in chemical structure from 
propanolol and which also have signi?cantly different 
biological pro?les [e.g., they may differ in potency, 
B-blocker receptor selectivity (B1 versus 3;), agonist 
properties and/ or membrane-stabilization activity] from 
that of propanolol, can nevertheless be advantageously 
formulated into novel nasal dosage forms and adminis 
tered nasally to provide enhanced bioavailability and 
minimized variations in blood levels as compared to 
oral dosage forms of those B-blockers, while at the same 
time providing relative ease of administration when 
compared to the intravenous route. The novel nasal 
dosage forms of the invention can be solutions, suspen 
sions, ointments or gels adapted for nasal administra 
tion. 
DETAILED DESCRIPTION OF THE 
INVENTION 
The selected B-blockers for use in the compositions 
and methods of the present invention are dichloroiso 
proterenol (DCI), pronethalol, sotalol, oxprenolol, pin 
dolol, metoprolol, nadoxolol, practolol, butoxamine, 
alprenolol, metalol, nifenalol, acebutolol, atenolol, 
bunolol, carteolol, labetalol, pamatolol, timolol, ti 
prenolol, xipranolol and bupranolol. Any pharmaceuti 
cally acceptable form of these B-blockers can be em 
ployed, i.e. the free base ora pharmaceutically accept 
able salt or ester thereof (e.g., oxprenolol hydrochlo 
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2 
ride, alprenolol hydrochloride, metoprolol tartrate, 
nadoxolol hydrochloride, pamatolol sulfate, timolol 
maleate, bupranolol hydrochloride, etc.); generally, the 
selected B-blocker is employed in the instant composi 
tions and method in the pharmaceutically acceptable 
form which has previously been found most advanta 
geous for oral or intravenous use. The structural formu 
lae for the free bases encompassed by the present inven 
tion are set forth below: 
dichloroiso- OH 
proterenol Cl | 
nciicmNHcmcl-mz 
Cl 
pronethalol 0H 
sotalol (|)H v ’ 
CHgSOgNH-Q- CHCH2NHCH(CH3)2 
oxprenolol 0H 
OCH2CHCH2NHCH(CH3)2 
OCH2CH=CH2 
pindolol Iii 
N 
OCH2(‘:HCH2NHCH(CH3)2 
OH 
metoprolol I 
cmocmcm-Q-ocr-lzcncnzNncmcnm 
OH 
nadoxolol , OH 
| /NH2 
OCl-I2CHCH2C\ 
. \Non 
practolol (IJH 
(Cl-I3)2CHNHCH2CHCH20—©—NI-I?CH; 
O 
butoxamine CH3 
HOCHCHNI-IC(CH3)3 
OCH3 
CH3O 
alprenolol 
OH 
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-continued 
metalol OH 
CH(|3HNHCH3 ' 5 
H1? CH3 
SOZCH3 
nifenalol (IJH ’ i 10 
O2N—©—CHCH1NHCH(CH3)2 
acebutolol . 
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55 
timolol S 
N/ \N OH 
I 
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4 
-continued 
xipranolol 
CH3 
OH 
ocmcncnmncmcm); 
CH3 
bupranolol H3O 
These B-blockers can be made by well-known methods. 
In accord with the present invention, the selected 
,B-blockers named supra can be administered nasally 
with results considerably superior to those obtained 
with oral administration in terms of enhanced drug 
bioavailability and minimization of blood level varia 
tions, thus enabling use of these B-blockers at lower 
dosage levels than was previously possible except in the 
case of intravenous administration. It would appear that 
these selected B-blockers are rapidly absorbed from the 
nasal mucosa into systemic blood without ?rst-pass 
metabolism. > 
Any of the selected B-blockers identi?ed above can 
be conveniently administered nasally to warm-blooded 
animals by formulating it into a nasal dosage form com 
prising the desired B-blocker, in an effective B-blocking 
amount, together with a nontoxic pharmaceutically 
acceptable nasal carrier therefor. As indicated earlier, 
the B-blocker can be employed in the form of the free 
base or in the form of a pharmaceutically acceptable salt 
or ester thereof. Suitable nontoxic pharmaceutically 
acceptable nasal carriers will be apparent to those 
skilled in the art of nasal pharmaceutical formulations. 
For those not skilled in the art, reference is made to the 
text entitled “REMINGTON’S PHARMACEUTI 
CAL SCIENCES”, 14th edition, 1970. Obviously, the 
choice of suitable carriers will depend on the exact 
nature of the particular nasal dosage form desired, e.g., 
whether the B-blocker is to be formulated into a nasal 
solution (for use as drops or as a spray), a nasal suspen 
sion, a nasal ointment or a nasal gel. Preferred nasal 
dosage forms are solutions, suspensions and gels, which 
contain a major amount of water (preferably puri?ed 
water) in addition to the active ingredient. Minor 
amounts of other ingredients such as pH adjusters (e.g., 
a base such as NaOH), emulsi?ers or dispersing agents, 
buffering agents, preservatives, wetting agents and jell 
ing agents (e.g., methylcellulose) may also be present. 
Most preferably, the nasal composition is isotonic, i».e. it 
has the same osmotic pressure as blood serum; If de 
sired, sustained release nasal compositions,‘ e.g. sus~ 
tained release gels, can be readily prepared, preferably 
by employingthe desired‘ B-blocker in 'one of its rela 
tively insoluble forms, such as the free base or an insolu? 
ble salt.v When the free base is not suf?ciently insoluble 
for sustained release compositions, or when a more 
highly insoluble form is desired, a long chain carboxylic 
acid salt of the desired B-blocker can be conveniently 
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employed. The carboxylic acid portion of the salt pref 
erably contains 10 to 20 carbon atoms. Such salts (e.g. 
stearates, palmitates etc.) can be readily synthesized, for 
example, by dissolving the hydrochloride salt of the 
B-blocker in water, then adding the alkali metal salt of 
the desired long chain carboxylic acid (e.g. sodium 
stearate). The corresponding long chain carboxylic acid 
salt which precipitates out of solution is removed by 
?ltration. Alternatively, equimolar amounts of the B 
blocker free base and the long chain carboxylic acid are 
combined in methanol. That mixture is then added to a 
small volume of water, causing the desired salt (e.g. 
B-blocker stearate) to precipitate out. 
Examples of the preparation of typical nasal composi 
tions containing selected B-blockers are set forth below. 
However, it is to be understood that these examples are 
given by way of illustration only and are not to be con 
strued as limiting the invention either in spirit or in 
scope as many modi?cations both in materials and in 
methods will be apparent to those skilled in the art. 
EXAMPLE 1 
2 Grams of sotalol hydrochloride are dissolved in 80 
ml of distilled water and the pH of the resultant solution 
is adjusted to 7.4 with dilute sodium hydroxide solution. 
A quantity of water suf?cient to bring the total volume 
to 100 ml is then added and suf?cient sodium chloride 
or other appropriate salt is added to adjust the solution 
to isotonicity. The solution is then sterilized by being 
passed through a 0.2 micron Millipore ?lter. The ?nal 
composition contains 2 mg of sotalol hydrochloride per 
0.1 ml of solution. 
The above procedure is repeated using 2 grams of 
oxprenolol hydrochloride in place of the sotalol hydro 
chloride. The resultant composition contains 2 mg of 
oxprenolol hydrochloride per 0.1 ml of solution. 
Repetition of the procedure of the ?rst paragraph of 
this example using 4 grams of metoprolol tartrate in 
place of the sotalol hydrochloride affords a nasal com 
position containing 4 mg of metoprolol tartrate per 0.1 
ml of solution. 
EXAMPLE 2 
15 Grams of alprenolol hydrochloride are combined 
with 80 ml of distilled water and the pH is adjusted to 
4.5 with dilute sodium hydroxide solution. A quantity of 
water suf?cient to bring the total volume to 100 ml is 
then added and suf?cient sodium chloride is added to 
adjust the solution to isotonicity. The solution is then 
sterilized by being passed through a 0.2 micron Mil 
lipore ?lter. The resultant composition contains 15 mg 
of alprenolol hydrochloride per 0.1 ml. 
The procedure described above is substantially re-' 
peated, except that 30 grams of pronethalol hydrobro 
mide are used in place of the alprenolol hydrochloride, 
affording a nasal composition containing 30 mg of 
pronethalol hydrobromide per 0.1 ml. 
EXAMPLE 3 
4 Grams of dichloroisoproterenol are dissolved in 80 
ml of isotonic saline solution and the pH of the resultant 
solution is adjusted to 7.0-7.2 with dilute hydrochloric 
acid. A quantity of isotonic saline suf?cient to bring the 
total volume to 100 ml is then added, and the solution is 
sterilized by being passed through a 0.2 micron Mil 
lipore ?lter. The resultant composition contains 4 mg of 
dichloroisoproterenol per 0.1 ml. 4 
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6 
Repetition of the foregoing procedure utilizing 8 
grams of sotalol in place of the dichloroisoproterenol 
affords a nasal composition containing 8 mg of sotalol 
per 0.1 ml. 
The procedure of the ?rst paragraph of this example 
is substantially repeated, save that 5 grams of pindolol 
are employed in place of the dichloroisoproterenol, to 
afford a nasal composition containing 5 mg of pindolol 
per 0.1 ml. 
EXAMPLE 4 
80 Grams of water are heated to 80° C. and 3.0 grams 
of Methocel are added, with stirring. The resultant 
mixture is allowed to stand at room temperature for 3 
hours. Then, 1.84 grams of oxprenolol stearate are sus 
pended in 20 grams of water, that suspension is added to 
the gel and thoroughly mixed, and the resultant viscous 
solution or gel is adjusted to isotonicity with sodium 
chloride. The sustained release composition thus ob 
tained contains 1.84 mg of oxprenolol stearate per 0.1 
ml. 
The above procedure is substantially repeated, except 
that 2.0 rather than 3.0 grams of Methocel are em 
ployed, and 3.0 grams of sotalol palmitate are substi 
tuted for the oxprenolol stearate. The sustained release 
composition prepared in this manner contains 3.0 mg of 
sotalol palmitate per 0.1 ml. 
Repetition of the procedure of the ?rst paragraph of 
this example, but using 2 grams of nadoxolol stearate in 
place of the oxprenolol stearate, affords a sustained 
release composition containing 2 mg of nadoxolol stea 
rate per .\0.1 ml. 
The procedure of the ?rst paragraph of this example 
is substantially repeated, except that 1.84 grams of di 
chloroisoproterenol palmitate are employed in place of 
the oxprenolol stearate. The resultant sustained release 
composition contains 1.84 mg of dichloroisoproterenol 
palmitate per 0.1 ml. 
Substitution of 20 grams of pronethalol myristate for 
the oxprenolol stearate used in the ?rst paragraph of 
this example and substantial repetition of the procedure 
there detailed afford a sustained release composition 
containing 20 mg‘ of pronethalol myristate per 0.1 ml. 
EXAMPLE 5 
The following are illustrative aqueous solutions of 
selected ,B-blockers suitable for use as nasal drops or 
nasal spray. In each case, the pH of the ?nal composi 
tion is adjusted to 7.4. If’ desired, the solutions are ad 
justed to isotonicity. 
Ingredient Amount 
w 
nadoxol hydrochloride 500 mg 
Tween 80 2 mg 
methylcellulose 20 mg 
water, puri?ed 10 ml 
w
bupranolol hydrochloride 750 mg 
Tween 80 3 mg 
methylcellulose 30 mg 
water, puri?ed 7 10 ml 
w
timolol maleate 800 mg 
Tween 80 ' 3 mg 
methylcellulose 20 mg 
water, puri?ed 10 ml 
4,428,883 
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Naturally, the therapeutic dosage range for nasal 
administration of the ,B-blockers according to the pres 
ent invention will vary with the size of the patient, the 
condition for which the drug is administered and the 
particular B-blocker employed. Generally, the daily 
dosage will approximate the amounts previously em 
ployed for intravenous administration of the particular 
,B-blocker involved. Thus, a typical dose of sotalol 
would be 1 to 10 mg administered nasally three times 
daily. The quantity of nasal dosage form needed to 
deliver the desired dose will of course depend on the 
concentration of B-blocker in the composition. The 
volume of solution or gel which would be needed to 
deliver the typical dose of sotalol speci?ed above would 
be 0.05 to 0.5 ml of 2% solution or gel. 
While the invention has been described in terms of 
various preferred embodiments, the skilled artisan will 
appreciate that various modi?cations, substitutions, 
omissions and additions may be made without departing 
from the spirit thereof‘. Accordingly, it is intended that 
the scope of the present invention be limited solely by 
the scope of the following claims. 
What is claimed is: 
1. A method for eliciting a systemic therapeutic ,8 
adrenergic blocking response in a warm-blooded ani 
mal, which comprises nasally administering to said ani 
mal a systemically therapeutically effective B-adrener 
gic blocking amount of dichloroisoproterenol, prone 
thalol, sotalol, oxprenolol, pindolol, metoprolol, nadox 
olol, practolol, butoxamine, alprenolol, metalol, nifena 
lol, acebutolol, atenolol, bunolol, carteolol, labetalol, 
pamatolol, timolol, tiprenolol, xipranolol or bupranolol, 
or a nontoxic pharmaceutically acceptable salt thereof. 
2. A method as de?ned by claim 1 for eliciting a 
systemic therapeutic B-adrenergic blocking response in 
a warm-blooded animal, which comprises nasally ad 
ministering to said animal a systemically therapeutically 
effective B-adrenergic blocking amount of dichloroiso 
proterenol, pronethalol, sotalol, oxprenolol, pindolol, 
alprenolol, metoprolol, nadoxolol, timolol or bu 
pranolol, or a nontoxic pharmaceutically acceptable 
acid addition salt thereof. 
15 
3. A method as de?ned by claim 1 for eliciting a , 
systemic therapeutic B-adrenergic blocking response in 
a warm-blooded animal, which comprises nasally ad 
ministering to said animal a systemically therapeutically 
effective B-adrenergic blocking amount of a long-chain 
carboxylic acid salt of dichloroisoproterenol, prone 
thalol, sotalol, oxprenolol, pindolol, metoprolol, nadox 
olol, practolol, butoxamine, alprenolol, metalol, nifena 
lol, acebutolol, atenolol, bunolol, carteolol, labetalol, 
pamatolol, timolol, tiprenolol, xipranolol or bupranolol, 
the carboxylic acid portion of said salt containing 10 to 
20 carbon atoms. 
4. A method for eliciting a systemic therapeutic B 
adrenergic response in a warm-blooded animal which 
comprises nasally administering to said animal, a sys 
temically therapeutically effective B-adrenergic block 
ing amount of a composition as de?ned. 
5. A method as de?ned by claim 1, wherein said 
warm-blooded animal is af?icted with angina pectoris. 
6. A method as de?ned by claim 1, wherein said 
warm-blooded animal is af?icted with arrhythmias. 
7. A method as de?ned by claim 1, wherein said 
warm-blooded animal is afflicted with hypertension. 
8. A method as de?ned by claim 1, wherein said 
warm-blooded animal is af?icted with migraine. 
55 
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9. A pharmaceutically acceptable, sustained release 
nasal composition, in dosage unit form, for nasal admin 
istration to obtain a systemic therapeutic B-adrenergic 
blocking response in a warm-blooded animal, consisting 
essentially of, per nasal dosage unit, (i) a systemically 
therapeutically effective unit B-adrenergic blocking 
amount of a long chain carboxylic acid salt of di 
chloroisoproterenol, pronethalol, sotalol, oxprenolol, 
pindolol, metoprolol, nadoxol, practolol, butoxamine, 
alprenolol, metalol, nifenalol, acebutolol, atenolol, 
bunolol, carteolol, labetalol, pamatolol, timolol, ti 
prenolol, xipranolol or bupranolol, the carboxylic acid 
portion of said salt containing 10 to 20 carbon atoms, 
and (ii) a nontoxic pharmaceutically acceptable nasal 
carrier therefor, said composition being in the form of a 
nasal ointment or a nasal gel. , 
10. The composition as de?ned by claim 9, wherein 
said salt is a stearate. 
11. The composition as de?ned by claim 9, wherein 
(i) is a systemically therapeutically effective unit B 
adrenergic blocking amount of a long chain carboxylic 
acid salt of dichloroisoproterenol. 
12. The composition as de?ned by claim 9, wherein 
(i) is a systemically therapeutically effective unit [3 
adrenergic blocking amount of a long chain carboxylic 
acid salt of pronethalol. 
13. The composition as de?ned by claim 9, wherein 
(i) is a systemically therapeutically effective unit [3 
adrenergic blocking amount of a long chain carboxylic 
acid salt of sotalol. 
14. The composition as de?ned by claim 9, wherein 
(i) is a systemically therapeutically effective unit B 
adrenergic blocking amount of a long chain carboxylic 
acid salt of oxprenolol. 
15. The composition as de?ned by claim 9, wherein 
(i) is a systemically therapeutically effective unit B 
adrenergic blocking amount of a long chain carboxylic 
acid salt of pindolol. 
16. The composition as de?ned by claim 9, wherein 
(i) is a systemically therapeutically effective unit [3 
adrenergic blocking amount of a long chain carboxylic 
acid salt of metoprolol. 
17. The composition as de?ned by claim 9, wherein 
(i) is a systemically therapeutically effective unit B 
adrenergic blocking amount of a long chain carboxylic 
acid salt of nadoxolol. 
' 18. The composition as de?ned by claim 9, wherein 
(i) is a systemically therapeutically effective unit ,8 
adrenergic blocking amount of a long chain carboxylic 
acid salt of practolol. - 
19. The composition as de?ned by claim 9, wherein 
(i) is a systemically therapeutically effective unit ,8 
adrenergic blocking amount of a long chain carboxylic 
acid salt of butoxamine. ' 
20. The composition as de?ned by claim 9, wherein 
(i) is a systemically therapeutically effective unit B 
adrenergic blocking amount of a long chain carboxylic 
acid salt of alprenolol. 
21. The composition as de?ned by claim 9, wherein 
(i) is a systemically therapeutically effective unit B 
adrenergic blocking amount of a long chain carboxylic 
acid salt of metalol. 
22. The composition as de?ned by claim 9, wherein 
(i) is a systemically therapeutically effective unit B 
adrenergic blocking amount of a long chain carboxylic 
acid salt of nifenalol. 
23. The composition as de?ned by claim 9, wherein 
(i) is a systemically therapeutically effective unit B 
4,428,883 
adrenergic blocking amount of a long chain carboxylic 
acid salt of acebutolol. 
24. The composition as de?ned by claim 9, wherein 
(i) is a systemically therapeutically effective unit B~ 
adrenergic blocking amount of a long chain carboxylic 
acid salt of atenolol. - ' 
25. The composition ‘as de?ned by claim 9, wherein 
(i) is a systemically therapeutically effective unit B 
adrenergic blocking amount of a long chain carboxylic 
acid salt of bunolol. ' 
26. The composition as de?ned by claim 9, wherein 
(i) is a systemically therapeutically effective unit B 
adrenergic blocking amount of a long chain carboxylic 
acid salt of carteolol. - ' . 
27. The composition as de?ned by claim 9, wherein 
(i) is a systemically therapeutically effective unit B 
adrenergic blocking amount of a long chain carboxylic 
acid salt of labetalol. 
28. The composition as de?ned by claim 9, wherein 
(i) is a systemically therapeutically effective unit [3 
adrenergic blocking amount of a long chain carboxylic 
acid salt of pamatolol. 
29. The composition as de?ned by claim 9, wherein 
(i) is a systemically therapeutically effective unit [3 
adrenergic blocking amount of a long chain carboxylic 
acid salt of timolol. ] 
30. The composition as de?ned by claim 9, wherein 
(i) is a systemically therapeutically effective unit B 
adrenergic blocking amount of a long chain carboxylic 
acid salt of tiprenolol. . ~ 
31. The composition as de?ned by claim 9, wherein 
(i) is a systemically therapeutically effective unit B 
adrenergicblocking amount of a long chain carboxylic 
acid salt of xipranolol. 
32. The composition as de?ned by claim 9, wherein 
(i) is a systemically therapeutically effective unit B 
adrenergic blocking amount of a long chain carboxylic 
acid salt of bupranolol. 
33. The composition as de?ned by claim 9, said com~ 
‘ position being in the form of a nasal ointment. 
34. The composition as de?ned by claim 9, said com 
position being in the form of a nasal gel. 
35. A pharmaceutically acceptable nasal composition, 
in dosage unit form, for nasal administration to obtain a 
systemic therapeutic B-adrenergic blocking response in 
a warm-blooded animal, consisting essentially of, per 
nasal dosage unit, (i) a systemically therapeutically ef 
fective unit B-adrenergic blocking amount of di 
chloroisoproterenol, pronethalol, sotalol, oxprenolol, 
pindolol, metoprolol, nadoxolol, practolol, butoxamine, 
alprenolol, metalol, nifenalol, acebutolol, atenolol, 
bunolol, carteolol, labetalol, pamatolol, timolol, ti 
prenolol, xipranolol or bupranolol, or a nontoxic phar 
maceutically acceptable salt thereof, and (ii) a nontoxic 
pharmaceutically acceptable nasal carrier therefor, said 
composition being in the form of a nasal ointment or a 
nasal gel adapted for sustained release to the nasal mu 
cosa. 
36. The composition as de?ned by claim 35, said 
composition being in the form of a nasal ointment. 
37. The composition as de?ned by claim 35, said 
composition being in the form of a nasal gel. 
38. The composition as de?ned by claim 35, wherein 
(i) is a systemically therapeutically effective unit ,8 
adrenergic blocking amount of dichloroisoproterenol or 
a nontoxic pharmaceutically acceptable acid addition 
salt thereof‘. 
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39. The composition as de?ned by claim 35, wherein 
(i) is a systemically therapeutically effective unit [3 
adrenergic blocking amount of pronethalol or a non 
toxic pharmaceutically acceptable acid addition salt 
thereof. 
40. The composition as de?ned by claim 35, wherein 
(i) is a systemically therapeutically effective unit [3 
adrenergic blocking amount of sotalol or a nontoxic 
pharmaceutically acceptable acid addition salt thereof. 
41. The composition as de?ned by claim 35, wherein 
(i) is a systemically therapeutically effective unit B 
adrenergic blocking amount of oxprenolol or a nontoxic 
pharmaceutically acceptable acid addition salt thereof. 
42. The composition as de?ned by claim 35, wherein 
(i) is a systemically therapeutically effective unit B 
adrenergic blocking amount of pindolol or a nontoxic 
pharmaceutically acceptable acid addition salt thereof. 
43. The composition as de?ned by claim 35, wherein 
(i) is a systemically therapeutically effective unit B 
adrenergic blocking amount of metoprolol or a non 
toxic pharmaceutically acceptable acid addition salt 
thereof. ' i 
44. The composition as de?ned by claim 35, wherein 
(i) is a systemically therapeutically effective unit ,8 
adrenergic blocking amount of nadoxolol or a nontoxic 
pharmaceutically acceptable acid addition salt thereof. 
45. The composition as de?ned by claim 35, wherein 
' (i) is a systemically therapeutically effective unit [3 
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adrenergic blocking amount of practolol or a nontoxic 
pharmaceutically acceptable acid addition salt thereof. 
46. The composition as de?ned by claim 35, wherein 
(i) is a (systemically therapeutically effective unit B 
adrenergic blocking amount of butoxamine or a non 
toxic pharmaceutically acceptable acid addition salt 
thereof. . v 
47. The composition as de?ned by claim 35, wherein 
(i) is a systemically therapeutically effective unit ,8 
adrenergic blocking amount of alprenolol or a nontoxic _ 
pharmaceutically acceptable acid addition salt thereof. 
48. The composition as de?ned by claim 35, wherein 
(i) is a systemically therapeutically effective unit ,8 
adrenergic blocking amount of metalol or a nontoxic 
pharmaceutically acceptable acid addition salt thereof. 
49. The composition as de?ned by claim 35, wherein 
(i) is a systemically therapeutically effective unit B 
adrenergic blocking amount of nifenalol or nontoxic 
pharmaceutically acceptable acid addition salt thereof. 
50. The composition as de?ned by claim 35, wherein 
(i) is a systemically therapeutically effective unit B 
adrenergic blocking amount of acebutolol or a nontoxic 
pharmaceutically acceptable acid addition salt thereof. 
51. The composition as de?ned by claim 35, wherein 
(i) is a systemically therapeutically effective unit B 
adrenergic blocking amount of atenolol or a nontoxic 
pharmaceutically acceptable acid addition salt thereof. 
52. The composition as de?ned by claim 35, wherein 
(i) is a systemically therapeutically effective unit B 
adrenergic blocking amount of bunolol or a nontoxic 
pharmaceutically acceptable acid addition salt thereof. 
53. The composition as de?ned by claim 35, wherein 
(i) is a systemically therapeutically effective unit [3 
adrenergic blocking amount of carteolol or a nontoxic 
pharmaceutically acceptable acid addition salt thereof. 
54. The composition as de?ned by claim 35, wherein 
(i) is a systemically therapeutically effective unit ,8 
adrenergic blocking amount of labetalol or a nontoxic 
pharmaceutically acceptable acid addition salt thereof. 
4,428,883 
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55. The composition as de?ned by claim 35, wherein 
(i) is a systemically therapeutically effective unit B 
adrenergic blocking amount of pamatolol or a nontoxic 
pharmaceutically acceptable acid addition salt thereof. 
56. The composition as de?ned by claim 35, wherein 
(i) is a systemically therapeutically effective unit B 
adrenergic blocking amount of timolol or a nontoxic. 
pharmaceutically acceptable acid addition salt thereof. 
57. The composition as de?ned by claim 35, wherein 
(i) is a systemically therapeutically effective unit ,8 
adrenergic blocking amount of tiprenolol or a nontoxic 
pharmaceutically acceptable acid addition salt thereof. 
58. The composition as de?ned by claim 35, wherein 
(i) is a systemically therapeutically effective unit [3 
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adrenergic blocking amount of xipranolol or a nontoxic 
pharmaceutically acceptable acid addition salt thereof. 
59. The composition as de?ned by claim 35, wherein 
(i) is a systemically therapeutically effective unit ,8 
adrenergic blocking amount of bupranolol or a nontoxic 
pharmaceutically acceptable acid addition salt thereof. 
60. A long chain carboxylic acid salt of dichloroiso 
proterenol, pronethalol, sotalol, oxprenolol, pindolol, 
metoprolol, nadoxolol, practolol, butoxamine, al 
prenolol, metalol, nifenalol, acebutolol, atenolol, buno 
lol, carteolol, labetalol, pamatolol, timolol, tiprenolol, 
xipranolol or bupranolol, the carboxylic acid portion of 
said salt containing 10 to 20 carbon atoms. 
61. A salt as de?ned by claim 60, said salt being a 
stearate. 
* =lr * * * 
